Investors have lost patience with Acacia Pharma Ltd., sinking the UK firm's stock after it suffered a second rejection from the US Food and Drug Administration for the post-operative nausea and vomiting (PONV) therapy Barhemsys, once again as a result of problems at the contract drug manufacturer.
Acacia was hit with its first complete response letter from the FDA in October 2018 which identified deficiencies that had been reported during an inspection of a facility of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?